Therapeutic product candidates

Other discovery programmes

Apitope is also progressing various peptide discovery programmes to further strengthen its pipeline:

ATX-MYO is currently in the discovery phase for the treatment of autoimmune myocarditis20.

Myocarditis is a disease marked by inflammation and damage of the heart muscle. Myocarditis and the associated disorder of dilated cardiomyopathy are the cause of approximately 45% of heart transplants in the US. It usually attacks otherwise healthy people and it is believed that 5 - 20% of all cases of sudden death in young adults are due to myocarditis.

As part of its product life-cycle management in MS, Apitope is also pursuing a discovery programme for ATX-MS2 and ATX-MS3 as follow-on product candidates targeting other self-antigens implicated in MS.

Apitope is a member of the RTCure consortium funded by the European Commission to identify peptides to treat rheumatoid arthritis.

The University of Birmingham has received grant support from the Wellcome Trust to fund the identification of peptides to treat primary biliary cholangitis in collaboration with Apitope.

20 Selli, M.E., Thomas, A.C., Wraith, D.C. and Newby, A.C. (2017) A humanized HLA-DR4 mouse model of autoimmune myocarditis. Journal of Molecular and Cellular Cardiology 107; 22–26.